Equine Aβ38 antibody and antigen (recombinant protein)

Diagnostic anti-Equine Aβ38 antibodies pairs and antigen for animal health (animal Equine/Horse Alzheimer Disease(AD)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine disease testing products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-EQU-AB38-Ag01Equine Aβ38$3090.00
GMP-EQU-AB38-Ab01Anti-Equine Aβ38 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB38-Ab02Anti-Equine Aβ38 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB38-Ab03Anti-Equine Aβ38 human monoclonal antibody (mAb)$3090.00
GMP-EQU-AB38-Ab04Anti-Equine Aβ38 human monoclonal antibody (mAb)$3090.00

Size： 1mg | 10mg | 100mg



Product Description

Cat No. GMP-EQU-AB38-Ag01
Product NameEquine Aβ38
Target/BiomarkerEquine Aβ38
Expression platformE.coli
IsotypesRecombinant Antigen
Bioactivity validationAnti-Equine Aβ38 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ38 level test of animal Equine/Horse with Alzheimer Disease(AD).
TagHis
Reconized/Reactive SpecicsEquine Aβ38
Product descriptionRecombinant Equine Aβ38 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB38-Ab01,GMP-EQU-AB38-Ab02
Target/BiomarkerEquine Aβ38
Product NameAnti-Equine Aβ38 mouse monoclonal antibody (mAb)
Expression platformCHO
Isotypes Mouse IgG
Bioactivity validationRecombinant Equine Aβ38 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ38 antibodies in Equine Aβ38 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ38 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ38 antibodies.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB38-Ab03,GMP-EQU-AB38-Ab04
Target/BiomarkerEquine Aβ38
Product NameAnti-Equine Aβ38 human monoclonal antibody (mAb)
Expression platformCHO
IsotypesHuman lgG1
Bioactivity validationRecombinant Equine Aβ38 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ38 antibodies in Equine Aβ38 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ38 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


    Equine Aβ38, also known as Amyloid Beta 38, emerges as a pivotal biomarker within the intricate realm of equine cognitive health. This unassuming peptide, a fragment of the amyloid precursor protein (APP), takes center stage in the unfolding drama of cognitive decline in aging horses. Structurally related to the broader family of amyloid beta peptides, Aβ38 plays a central role in the formation of amyloid plaques within the equine brain, a hallmark of neurodegenerative conditions like equine cognitive dysfunction (ECD).

    In the complex milieu of the equine central nervous system, Aβ38's story unfolds. It is involved in the generation of amyloid plaques that can accumulate over time, gradually compromising cognitive function and behavior in horses. ECD, akin to human dementia, casts a shadow on the twilight years of aging equine companions, affecting memory, spatial awareness, and overall cognitive abilities.

    Understanding Equine Aβ38 is akin to deciphering a critical chapter in the narrative of equine cognitive health. Its presence and levels in the brain offer insights into the progression of neurodegenerative processes in horses, guiding our comprehension of ECD and related conditions. Monitoring Aβ38 levels equips researchers and veterinarians with a lens through which to observe the course of cognitive decline, helping to unlock potential interventions and therapies aimed at enhancing the quality of life for aging equine companions.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.